SEARCH

SEARCH BY CITATION

References

  • Anonymous: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997, 41, 813.
  • Abdalla, S. I., P. Lao-Sirieix, M. R. Novelli, L. B. Lovat, I. R. Sanderson & R. C. Fitzgerald: Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin. Cancer Res. 2004, 10, 47844792.
  • Aly, A., A. Shulkes & G. S. Baldwin: Gastrins, cholecystokinins and gastrointestinal cancer. Biochim. Biophys. Acta 2004, 1704, 110.
  • Armstrong, D.: Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease. Lancet 2000, 356, 610612.
  • Baba, M., K. Itoh & M. Tatsuta: Glycine-extended gastrin induces matrix metalloproteinase-1- and -3 mediated invasion of human colon cancer cells through type I collagen gel and Matrigel. Int. J. Cancer 2005, 111, 2331.
  • Baldwin, G. S.: The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth. J. Gastroenterol. Hepatol. 1995, 10, 215232.
  • Baldwin, G. S. & A. Shulkes: Gastrin as an autocrine growth factor in colorectal carcinoma: implications for therapy. World J. Gastroenterol. 1998a, 4, 461463.
  • Baldwin, G. S. & A. Shulkes: Gastrin, gastrin receptors and colorectoral carcinoma. Gut 1998b, 42, 581584.
  • Bellou, A., I. Aimone-Gastrin, J. D. De Korwin, J. P. Bronowicki, A. Moneret-Vautrin, J. P. Nicolas, M. A. Bigard & J. L. Gueant: Cobalamin deficiency with megaloblastic anaemia in one patient under longterm omeprazole therapy. J. Intern. Med. 1996, 240, 161164.
  • Berstad, A. E., J. G. Hatlebakk, H. Maartmann-Moe, A. Berstad & P. Brandtzaeg: Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997, 41, 740747.
  • Bezwoda, W., R. Charlton, T. Bothwell, J. Torrance & F. Mayet: The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J. Lab. Clin. Med. 1978, 92, 108116.
  • Borch, K., E. Kullman, S. Hallhagen, T. Ledin & I. Ihse: Increased incidence of pancreatic neoplasia in pernicious anemia. World J. Surg. 1988, 12, 866870.
  • Borch, K., H. Renvall & G. Liedberg: Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985, 88, 638648.
  • Borch, K., H. Renvall, G. Liedberg & B. N. Andersen: Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand. J. Gastroenterol. 1986, 21, 357363.
  • Bordi, C., C. Azzoni, G. Ferraro, V. D. Corleto, F. Gibril, G. Delle Fave, I. A. Lubensky, D. J. Venzon & R. T. Jensen: Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Amer. J. Clin. Pathol. 2000, 114, 419425.
  • Bordi, C., T. D'Adda, C. Azzoni, F. P. Pilato & P. Caruana: Hypergastrinemia and gastric enterochromaffinlike cells. Amer. J. Surg. Pathol. 1995, 19, S8S19.
  • Bordi, C., T. D'Adda, F. P. Pilato & C. Ferrari: Carcinoid (ECL cell) tumor of the oxyntic mucosa of the stomach: a hormone-dependent neoplasm? In: Progress in surgical pathology. (vol. 8). Eds.C.Fenoglio-Preiser, M.Wolff & F.Rilke. Field & Wood, Philadelphia, 1988, pp. 177195.
  • Brinton, L. A., G. Gridley, Z. Hrubeck, R. Hoover & J. F. Fraumeni, Jr.: Cancer risk following pernicious anaemia. Brit. J. Cancer 1989, 89, 810813.
  • Buchan, A. M. J., S. Grant & H. J. Freeman: Regulatory peptides in Barrett's oesophagus. J. Pathol. 1985, 146, 227234.
  • Cadiot, G., T. Lehy, P. Ruszniewski, S. Bonfils & M. Mignon: Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment. Dig. Dis. Sci. 1993, 38, 13071317.
  • Cadiot, G., C. Vissuzaine, F. Potet & M. Mignon: Fundic argyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome. Dig. Dis. Sci. 1995, 40, 12751278.
  • Caplin, M., K. Khan, S. Grimes, D. Michaeli, K. Savage, R. Pounder & A. Dhillon: Effect of gastrin and anti-gastrin antibodies on proliferation of hepatocyte cell lines. Dig. Dis. Sci. 2001, 46, 13561366.
  • Carney, J. A., V. L. W. Go, J. F. Fairbanks, S. B. Moore, E. C. Alport & E. E. Nora: The syndrome of gastric argytrophil carcinoid tumors and nonantral gastric atropy. Ann. Intern. Med. 1983, 99, 761766.
  • Chu, M., F. C. Nielsen, L. Franzen, J. F. Rehfeld, J. J. Holst & K. Borch: Effect of endogenous hypergastrinemia on gastrin receptor expressing human colon carcinoma transplanted to athymic rats. Gastroenterology 1995, 109, 14151420.
  • Clere, P., M. Dufresne, C. Saillan, E. Chastre, T. Andre, C. Escrieut, K. Kennedy, N. Vaysse, C. Gespach & D. Fourmy: Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon. Int. J. Cancer 1997, 72, 931936.
  • Collen, M. J., J. M. Howard, K. E. McArthur, J. P. Raufman, M. J. Cornelius, C. A. Ciarleglio, J. D. Gardner & R. T. Jensen: Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann. Intern. Med. 1984, 100, 5258.
  • Conrad, M. E.: Iron absorption. In: Physiology of the gastrointestinal tract, 2nd ed.. Ed.L. R.Johnson. Raven Press, New York, 1987, pp. 14371453.
  • Coupe, M., H. Rees, C. J. Springer, A. E. Bishop, J. A. Morris, J. M. Polak & J. Calam: Gastric enterochromaffin-like (ECL) cells in hypergastrinaemic duodenal ulcer disease. Gut 1990, 31, 144147.
  • Creutzfeldt, R., R. Lamberts, F. Stockmann & G. Brunner: Quantitative studies of gastric endocrine cells in patients receiving long-term treatment with omeprazole. Scand. J. Gastroenterol. 1989, 24, 122128.
  • Creutzfeldt, W.: Consequences of gastric acid inhibition in man. In: Proton pump inhibitors. Ed.L.Olbe. Birkhauser Verlag, Basel, Switzerland, 1999, pp. 91115.
  • Creutzfeldt, W.: The achlorhydria-carcinoid sequence: role of gastrin. Digestion 1988, 39, 6179.
  • Creutzfeldt, W. & R. Lamberts: Is hypergastrinemia dangerous to man? Scand. J. Gastroenterol. 1991, 180 (Suppl.), 179191.
  • D'Adda, T., V. Corleto, F. P. Pilato, M. T. Baggi, F. Robutti, G. Delle Fave & C. Bordi: Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Correspondence with light microscopic findings. Gastroenterology 1990, 99, 1726.
  • De Leval, L., N. Hardy, M. Deprez, J. Delwaide, J. Belaiche & J. Boniver: Gastric collision between a papillotubular adenocarcinoma and a gastrinoma in a patient with Zollinger-Ellison syndrome. Virchows Arch. 2002, 441, 462465.
  • Delle Fave, G., M. Marignani, A. Moretti, G. D'Ambra, G. Martino & B. Annibale: Hypergastrinemia and enterochromaffin-like cell hyperplasia. Yale J. Biol. Med. 1998, 71, 291301.
  • Dickinson, C. J.: Relationship of gastrin processing to colon cancer (Editorial). Gastroenterology 1995, 109, 13841388.
  • Diebold, M. D., S. Richardson, A. Duchteau, M. A. Bigard, R. Colin, A. Cortot, J. L. Fauchere & P. Zeitoun: Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls. Dig. Dis. Sci. 1998, 43, 16291635.
  • Dutta, S. K.: Editorial: vitamin B12 malabsorption and omeprazole therapy. J. Am. Coll. Nutr. 1994, 13, 544545.
  • Eason, C. T., A. J. Spencer, A. Pattison, D. D. Howells, D. C. Henry & F. W. Bonner: Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse, and marmoset. Toxicol. Appl. Pharmacol. 1988, 95, 328338.
  • Eissele, R., G. Brunner, B. Simon, E. Solcia & R. Arnold: Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997, 112, 707717.
  • El-Omar, E., S. Banerjee, A. Wirz, I. Penman, J. E. Ardill & K. E. McColl: Marked rebound acid hypersecretion after treatment with ranitidine. Amer. J. Gastroenterol. 1996, 91, 355359.
  • El-Serag, H. B., T. V. Aguirre, S. Davis, M. Kuebeler, A. Bhattacharyya & R. E. Sampliner: Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Amer. J. Gastroenterol. 2005, 99, 18771883.
    Direct Link:
  • Elsborg, L. & J. Mosbech: Pernicious anaemia as a risk factor in gastric cancer. Acta med. scand. 1979, 206, 315318.
  • Eriksson, S., L. Clase & I. Moquist-Olsson: Pernicious anemia as a risk factor in gastric cancer. The extent of the problem. Acta med. scand. 1981, 210, 481484.
  • Festen, H. & J. Tertoolen: Malabsorption of protein-bound but not unbound cobalamin during treatment with omeprazole. Gastroenterology 1988, 94, A125.
  • Festen, H. P.: Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand. J. Gastroenterol. 1991, 26, 17.
  • Feurle, G. E.: Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome. Gut 1994, 35, 275277.
  • Fich, A., N. J. Talley, R. G. Shorter & S. F. Philips: Zollinger-Ellison syndrome. Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion. Dig. Dis. Sci. 1991, 36, 1014.
  • Flejou, J. F.: Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 2005, 54, i6i12.
  • Fossmark, R., G. Johnsen, E. Johanessen & H. L. Waldum: Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment. Pharmacol. Ther. 2005a, 21, 149154.
  • Fossmark, R., C. M. Zhao, T. C. Martinsen, S. Kawase, D. Chen & H. L. Waldum: Dedifferentiation of enterochromaffin-like cells in gastric cancer of hypergastrinemic cotton rats. APMIS 2005b, 113, 436449.
  • Freston, J. W.: Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Ann. Intern. Med. 1994, 121, 232233.
  • Frucht, H., P. N. Maton & R. T. Jensen: Use of omeprazole in patients with the Zollinger-Ellison syndrome. Dig. Dis. Sci. 1991, 36, 394404.
  • Geboes, K., W. Dekker, C. J. Mulder, K. Nusteling & Dutch Study Group: Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment. Pharmacol. Ther. 2001, 15, 18191826.
  • Gillen, D. & K. E. McColl: Problems associated with the clinical use of proton pump inhibitors. Pharmacology & Toxicology 2001a, 89, 281286.
  • Gillen, D. & K. E. McColl: Problems related to acid rebound and tachyphylaxis. Best Pract. Res. Clin. Gastroenterol. 2001b, 15, 487495.
  • Gillen, D., A. A. Wirz, J. E. Ardill & K. E. McColl: Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999a, 116, 239247.
  • Gillen, D., A. A. Wirz & K. E. L. McColl: Rebound acid hypersecretion after omeprazole is a prolonged phenomenon. Gut 2000, 46, W75.
  • Gillen, D., A. A. Wirz & K. E. L. McColl: Rebound maximal acid hypersecretion after omeprazole persists to at least 11 months after treatment. Gastroenterology 2001, 120, A158.
  • Gillen, D., A. A. Wirz, W. D. Neithercut, J. E. Ardill & K. E. McColl: Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999b, 44, 468475.
  • Golubov, J., P. Flanagan & P. Adams: Inhibition of iron absorption by omeprazole in rat model. Dig. Dis. Sci. 1991, 36, 405408.
  • Gough, D. B., G. B. Thompson, T. B. Crotty, J. H. Donohue, L. K. Kvols, J. A. Carney, C. S. Grant & D. M. Nagorney: Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J. Surg. 1994, 18, 473480.
  • Green, D. M., A. E. Bishop, G. Rindi, F. I. Lee, M. J. Daly, J. Domin, S. R. Bloom & J. M. Polak: Enterochromaffin-like cell populations in human fundic mucosa: quantitative studies of their variations with age, sex, and plasma gastrin levels. J. Pathol. 1989, 157, 235241.
  • Guo, Y. S. & C. M. Townsend, Jr.: Roles of gastrointestinal hormones in pancreatic cancer. J. Hepatobiliary Pancreat. Surg. 2000, 7, 276285.
  • Haigh, C. R., S. E. Attwood, D. G. Thompson, J. A. Jankowski, C. M. Kirton, D. M. Pritchard, A. Varro & R. Dimaline: Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003, 124, 615625.
  • Harris, J. C., P. A. Clarke, A. Awan, J. Jankowski & S. A. Watson: An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res. 2004a, 64, 19151919.
  • Harris, J. C., A. D. Gilliam, A. J. McKenzie, S. A. Evans, A. M. Grabowska, P. A. Clarke, D. F. McWilliams & S. A. Watson: The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas. Cancer Res. 2004b, 64, 56245631.
  • Hatlebakk, J. G., A. Hyggen, P. H. Madsen, P. O. Walle, T. Schulz, P. Mowinckel, T. Bernklev & A. Berstad: Heartburn treatment in primary care: randomised, double blind study for 8 weeks. Brit. Med. J. 1999, 319, 550553.
  • Havu, N.: Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986, 35 (Suppl. 1), 4255.
  • Håkanson, R., J. Axelson, R. Ekman & F. Sundler: Hypergastrinaemia evoked by omeprazole stimulates growth of gastric mucosa but not of pancreas of intestines in hamster, guinea pig and chicken. Regul. Pept. 1988, 23, 105115.
  • Håkanson, R., H. Blom, E. Carlsson, H. Larsson, B. Ryberg & F. Sundler: Hypergastrinemia produces trophic effects in stomach but not in pancreas and intestines. Regul. Pept. 1986, 13, 225233.
  • Håkanson, R. & F. Sundler: Mechanisms for the development of gastric carcinoids. Digestion 1986, 35 (Suppl. 1), 1151.
  • Helander, H. F., K. Rutgersson, K. G. Helander, J. P. Pisegna, J. D. Gardner, R. T. Jensen & P. N. Maton: Stereologic investigations of human gastric mucosa: II. Oxyntic mucosa from Zollinger-Ellison syndrome. Scand. J. Gastroenterol. 1992, 27, 875883.
  • Hillman, L. C., L. Chiragakis, B. Shadbolt, G. L. Kaye & A. C. Clarke: Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med. J. Aust. 2004, 180, 387391.
  • Hirschowitz, B. I. & M. M. Haber: Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment. Pharmacol. Ther. 2001, 15, 87103.
  • Hirschowitz, B. I., J. Simmons & J. Mohnen: Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment. Pharmacol. Ther. 2001, 15, 17951806.
  • Hirschowitz, B. I., J. Simmons & J. Mohnen: Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin. Gastroenterol. Hepatol. 2005, 3, 3948.
  • Holtmann, G., C. Cain & P. Malfertheiner: Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999, 117, 1116.
  • Howard, J. M., A. N. Chremos, M. J. Collen, K. E. McArthur, J. A. Cherner, P. N. Maton, C. A. Ciarleglio, M. J. Cornelius, J. D. Gardner & R. T. Jensen: Famotidine, a new, potent, long-acting histamine H2receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 1985, 88, 10261033.
  • Hsing, A. W., L. E. Hansson, J. K. McLaughlin, O. Nyren, W. J. Blot, A. Ekbom & J. F. Fraumeni, Jr.: Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993, 71, 745750.
  • Jansen, J. B., E. C. Klinkenberg-Knol, S. G. Meuwissen, J. W. De Bruijne, H. P. Festen, P. Snel, A. E. Luckers, I. Biemond & C. B. Lamers: Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990, 99, 621628.
  • Jensen, R. T.: Recent insights from studies of gastrinomas. In: Gastrin in the new millenium (2004). Eds.J. L.Merchant, A. M. J.Buchan & T. C.Wang. The CURE Foundation, Los Angeles, CA, 2004, pp. 339352.
  • Jensen, R. T.: Use of omeprazole and other proton pump inhibitors in the Zollinger-Ellison syndrome. In: Milestones in Drug Therapy. Ed.L.Olbe. Birkhauser Verlag AG Publish. Co., Basel, Switzerland, 1999, pp. 205221.
  • Jensen, R. T.: Gastrinoma as a model for prolonged hypergastrinemia in man. In: Gastrin. Ed.J. H.Walsh. Raven Press Publishing Co., New York, NY, 1993, pp. 373393.
  • Jensen, R. T.: Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacology & Toxicology 2002, 91, 333350.
  • Jensen, R. T., M. J. Collen, K. E. McArthur, J. M. Howard, P. N. Maton, J. A. Cherner & J. D. Gardner: Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric acid hypersecretory states. Amer. J. Med. 1984, 77(5B), 90105.
  • Jensen, R. T. & J. D. Gardner: Gastrinoma. In: The pancreas: Biology, pathobiology and disease. 2 edn. Eds.V. L. W.Go, E. P.DiMagno, J. D.Gardner, E.Lebenthal, H. A.Reber & G. A.Scheele. Raven Press Publishing Co., New York, 1993, pp. 931978.
  • Jensen, R. T., D. C. Metz, P. D. Koviack & K. M. Feigenbaum: Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome. Aliment. Pharmacol. Ther. 1993, 7 (Suppl. 1), 4150.
  • Karlson, B. M., A. Ekbom, S. Waeholder, J. K. McLaughlin & A. W. Hsing: Cancer of the upper gastrointestinal tract among patients with pernicious anemia: a case-cohort study. Scand. J. Gastroenterol. 2001, 35, 847851.
  • Kittang, E., E. Aadland, H. Schjonsby & K. Rohss: The effect of omeprazole on gastric acidity and the absorption of liver cobalamins. Scand. J. Gastroenterol. 1987, 22, 156160.
  • Kittang, E., E. Aadlang & H. Schonsby: Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man. Gut 1985, 26, 594598.
  • Klinkenberg-Knol, E. C., H. P. M. Festen, J. B. M. J. Jansen, C. B. H. W. Lamers, F. Nelis, P. Snel, A. Luckers, C. P. M. Dekkers, N. Havu & S. G. M. Meuwissen: Long-term treatment wih omeprazole for refractory reflux esophagitis: efficacy and safety. Ann. Intern. Med. 1994, 121, 161167.
  • Klinkenberg-Knol, E. C., F. Nelis, J. Dent, P. Snel, B. Mitchell, P. Prichard, D. Lloyd, N. Havu, M. H. Frame, J. Roman, A. Walan & a long-term study group: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000, 118, 661669.
  • Koh, T. J.: Extragastric effects of gastrin gene knock-out mice. Pharmacology & Toxicology 2002, 91, 368374.
  • Kokkola, A., S. M. Sjoblom, R. Haapiainen, P. Sipponen, P. Puolakkainen & H. Jarvinen: The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand. J. Gastroenterol. 1998, 33, 8892.
  • Konturek, P. C., A. Nikiforuk, J. Kania, M. Raithel, E. G. Hahn & S. Mühldorfer: Activation of NFκ represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARγ and growth factors. Dig. Dis. Sci. 2004, 49, 10751083.
  • Koop, H.: Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment. Pharmacol. Ther. 1992, 6, 399406.
  • Koop, H. & M. G. Bachem: Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J. Clin. Gastroenterol. 1992, 14, 288292.
  • Kuipers, E. J., L. Lundell, E. C. Klinkenberg-Knol, N. Havu, H. P. Festen, B. Liedman, C. B. Lamers, J. B. Jansen, J. Dalenback, P. Snel, G. F. Nelis & S. G. Meuwissen: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. New Engl. J. Med. 1996, 334, 10181022.
  • Kuipers, E. J. & S. G. M. Meuwissen: The efficacy and safety of long-term omeprazole treatment for gastroesophageal reflux disease. Gastroenterology 2000, 118, 795801.
  • Kuipers, E. J., G. F. Nelis, E. C. Klinkenberg-Knol, P. Snel, D. Goldfain, J. J. Kolkman, H. P. Festen, J. Dent, P. Zeitoun, N. Havu, M. Lamm & A. Walan: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004, 53, 1220.
  • Kuipers, E. J., A. M. Uyterlinde, A. S. Pena, H. J. Hazenberg, E. Bloemena, J. Lindeman, E. C. KlinkenbergKnol & S. G. Meuwissen: Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Amer. J. Gastroenterol. 1995, 90, 14011406.
  • Labenz, J., A. L. Blum, E. Bayerdorffer, A. Meining, M. Stolte & G. Borsch: Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997, 112, 14421447.
  • Laine, L., D. Ahnen, C. McClain, E. Solcia & J. H. Walsh: Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment. Pharmacol. Ther. 2000, 14, 651668.
  • Lamberts, R., W. Creutzfeldt, F. Stockmann, U. Jacubaschke, S. Maas & G. Brunner: Long term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988, 39, 126135.
  • Lamberts, R., W. Creutzfeldt, H. G. Struber, G. Brunner & E. Solcia: Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993, 104, 13561370.
  • Larsson, H., E. Carlsson, B. Ryberg, J. Fryklund & B. Wallmark: Rat parietal cell function after prolonged inhibition of gastric acid secretion. Amer. J. Physiol. 1988, 254, G33G39.
  • Lehy, T., G. Cadiot, M. Mignon, P. Ruszniewski & S. Bonfils: Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992, 33, 12751279.
  • Lehy, T., M. Mignon, G. Cadiot, L. Elouaer-Blanc, P. Ruszniewski, M. J. Lewin & S. Bonfils: Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment. Gastroenterology 1989, 96, 10291040.
  • Ley, L. M., A. Becker, R. Luhmann, P. Sander & P. W. Lucker: Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine. Meth. Find. Exp. Clin. Pharmacol. 2005, 27, 2529.
  • Ligumsky, M., J. Lysy, G. Siguencia & Y. Friedlander: Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J. Clin. Gastroenterol. 2001, 33, 3235.
  • Lindenbaum, J., I. H. Rosenberg, P. W. Wilson, S. P. Stabler & R. H. Allen: Prevalence of cobalamin deficiency in the Framingham elderly population. Amer. J. Clin. Nutr. 1994, 60, 211.
  • Lundell, L., P. Miettinen, H. E. Myrvold, S. A. Pedersen, K. Thor, A. Andersson, J. Hattlebakk, N. Havu, E. Janatuinen, K. Levander, B. Liedman & P. Nystrom: Lack of effect of acid suppression therapy on gastric atrophy. Nordic gerd study group. Gastroenterology 1999, 117, 319326.
  • Malfertheiner, P., F. Megraud, C. O'Morain, A. P. Hungin, R. Jones, A. Axon, D. Y. Graham & G. Tytgat: Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol Ther. 2002a, 16, 167180.
  • Malfertheiner, P., F. Megraud, C. O'Moran, A. P. Hungin, R. Jones, A. Axon, D. Y. Graham, G. Tytgat & European Helicobacter Pylori Study Group (EHPSG): Current concepts in the management of Helicobacter pylori infection – the Maastricht 2 – 2000 Consensus Report. Aliment. Pharmacol. Ther. 2002b, 16, 167180.
  • Marcuard, S. P., L. Albernaz & P. G. Khazanie: Omeprazole therapy causes malabsorption of cyanocobalamin (Vitamin B12). Ann. Intern. Med. 1994, 120, 211215.
  • Maton, P.: Risks of hypergastrinemia. Dig. Dis. Sci. 1995, 13, 12.
  • Maton, P. N., E. E. Lack, M. J. Collen, M. J. Cornelius, E. David, J. D. Gardner & R. T. Jensen: The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990, 99, 943950.
  • Maton, P. N., J. A. Norton, L. K. Nieman, J. L. Doppman & R. T. Jensen: Multiple endocrine neoplasia type II with Zollinger-Ellison syndrome caused by a solitary pancreatic gastrinoma. J. Amer. Med. Ass. 1989a, 262, 535537.
  • Maton, P. N., R. Vinayek, H. Frucht, K. A. McArthur, L. S. Miller, Z. A. Saeed, J. D. Gardner & R. T. Jensen: Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989b, 97, 827836.
  • Mattsson, H., N. Havu, J. Brautigam, K. Carlsson, L. Lundell & E. Carlsson: Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 1991, 100, 311319.
  • McColl, K. E.: Helicobacter pylori infection and long term proton pump inhibitor therapy. Gut 2004, 53, 57.
  • Metz, D. C., R. V. Benya, V. A. Fishbeyn, J. R. Pisegna, M. Orbuch, D. B. Strader, J. A. Norton & R. T. Jensen: Prospective study of the need for long-term antisecretory therapy in patients with ZollingerEllison syndrome following successful curative gastrinoma resection. Aliment. Pharmacol. Ther. 1993a, 7 (#3), 247257.
  • Metz, D. C. & R. T. Jensen: Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: Endocrine Tumors of the Pancreas: Recent advances in research and management. Series: Frontiers of Gastrointestinal Research. Eds.M.Mignon & R. T.Jensen. S. Karger, Basel, Switzerland, 1995, pp. 240257.
  • Metz, D. C., J. R. Pisegna, V. A. Fishbeyn, R. V. Benya, K. M. Feigenbaum, P. D. Koviack & R. T. Jensen: Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992, 103, 14981508.
  • Metz, D. C., J. R. Pisegna, G. L. Ringham, K. M. Feigenbaum, P. D. Koviack, P. N. Maton, J. D. Gardner & R. T. Jensen: Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig. Dis. Sci. 1993b, 38, 245256.
  • Metz, D. C., D. B. Strader, M. Orbuch, P. D. Koviack, K. M. Feigenbaum & R. T. Jensen: Use of omeprazole in Zollinger-Ellison: A prospective nine-year study of efficacy and safety. Aliment. Pharmacol. Ther. 1993c, 7, 597610.
  • Meuwissen, S. G., M. E. Craanen & E. J. Kuipers: Gastric mucosal morphological consequences of acid suppression: a balanced view. Best Pract. Res. Clin Gastroenterol. 2001, 15, 497510.
  • Miller, L. S., R. Vinayek, H. Frucht, J. D. Gardner, R. T. Jensen & P. N. Maton: Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990, 98, 341346.
  • Mitchell, S. L. & K. Rockwood: The association between antiulcer medication and initiation of cobalamin replacement in older persons. J. Clin. Epidemiol. 2001, 54, 531534.
  • Moayyedi, P., C. Wason, R. Peacock, A. Walan, K. Bardhan, A. T. Axon & M. F. Dixon: Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobactor 2000, 5, 206214.
  • Modlin, I. M., K. D. Lye & M. Kidd: Carcinoid tumors of the stomach. Surg. Oncol. 2003, 12, 153172.
  • Modlin, I. M. & L. H. Tang: The gastric enterochromaffin-like cell: an enigmatic cellular link. Gastroenterology 1996, 111, 783810.
  • Moore, T. C., L. I. Jepeal, M. O. Boylan, S. K. Singh, N. Boyd, D. G. Beer, A. J. Chang & M. M. Wolfe: Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma cells. Regul. Pept. 2004, 120, 195203.
  • Morisset, J., J. Laine, M. Biernat & S. Julien: What are the pancreatic target cells for gastrin and its CCKB receptor? Is this a couple for cancerous cells? Med. Sci. Monit. 2004, 10, RA246.
  • Morris, C. D., G. R. Armstrong, G. Bigley, H. Green & S. E. Attwood: Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Amer. J. Gastroenterol. 2001, 96, 990996.
  • Naunton, M., G. M. Peterson & M. D. Bleasel: Overuse of proton pump inhibitors. J. Clin. Pharm. Ther. 2000, 25, 330340.
  • Norton, J. A., H. R. Alexander, D. L. Fraker, D. J. Venzon & R. T. Jensen: Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann. Surg. 2004a, 239, 617626.
  • Norton, J. A., D. L. Fraker, H. R. Alexander, D. J. Venzon, J. L. Doppman, J. Serrano, S. U. Goebel, P. Peghini, P. K. Roy, F. Gibril & R. T., Jensen: Surgery to cure the Zollinger-Ellison syndrome. New Engl. J. Med. 1999, 341, 635644.
  • Norton, J. A. & R. T. Jensen: Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann. Surg. 2004, 240, 757773.
  • Norton, J. A., M. L. Melcher, F. Gibril & R. T. Jensen: Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgery. Surgery 2004b, 136, 12671274.
  • Orbuch, M., D. J. Venzon, I. A. Lubensky, H. C. Weber, F. Gibril & R. T. Jensen: Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Dig. Dis. Sci. 1996, 41, 604613.
  • Peghini, P. L., B. Annibale, C. Azzoni, M. Milione, V. D. Corleto, F. Gibril, D. J. Venzon, G. Delle Fave, C. Bordi & R. T. Jensen: Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002, 123, 6885.
  • Pisegna, J. R., J. A. Norton, G. G. Slimak, D. C. Metz, P. N. Maton & R. T. Jensen: Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992, 102, 767778.
  • Poynter, D., C. R. Pick, R. A. Harcourt, S. A. Selway, G. Ainge, I. W. Harman, N. W. Spurling, P. A. Fluck & J. L. Cook: Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut 1985, 26, 12841295.
  • Poynter, D., S. A. Selway, S. A. Papworth & S. R. Riches: Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockade. Gut 1986, 27, 13381346.
  • Prewett, E. J., M. Hudson, C. U. Nwokolo, A. M. Sawyerr & R. E. Pounder: Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology 1991, 100, 873877.
  • Qvigstad, G., J. S. Arnestad, E. Brenna & H. L. Waldum: Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Scand. J. Gastroenterol. 1998, 33, 12441248.
  • Qvigstad, G., S. Falkmer, B. Westre & H. L. Waldum: Clinical and histopathological tumour progression in ECL cell carcinoids (“ECLomas”). APMIS 1999, 107, 10851092.
  • Qvigstad, G., T. Qvigstad, B. Westre, A. K. Sandvik, E. Brenna & H. L. Waldum: Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS 2002, 110, 132139.
  • Qvigstad, G., A. K. Sandvik, E. Brenna, S. Aase & H. L. Waldum: Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. Histochem. J 2000, 32, 551556.
  • Qvigstad, G. & H. Waldum: Rebound hypersecretion after inhibition of gastric acid secretion. Basic & Clinal Pharmacology & Toxicology 2004, 94, 202208.
  • Rehfeld, J. F.: Gastrin and colorectal cancer: A never-ending dispute? (Editorial). Gastroenterology 1995, 108, 13071310.
  • Rehfeld, J. F. & W. W. Van Solinge: The tumor biology of gastrin and cholecystokinin. Adv. Cancer Res. 1994, 63, 295347.
  • Reilly, J. P.: Safety profile of the proton-pump inhibitors. Am. J. Health Syst. Pharm. 1999, 56, S11S17.
  • Renga, M., G. Brandi, G. M. Paganelli, C. Calabrese, S. Papa, A. Tosti, P. Tomassetti, M. Miglioli & G. Biasco: Rectal cell proliferation and colon cancer risk in patients with hypergastrinemia. Gut 1997, 41, 330332.
  • Rindi, G., C. Azzoni, S. La Rosa, C. Klersy, D. Paolotti, S. Rappel, M. Stolte, C. Capella, C. Bordi & E. Solcia: ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999, 116, 532542.
  • Rindi, G., C. Bordi, S. Rappel, S. La Rosa, M. Stolte & E. Solcia: Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J. Surg. 1996, 20, 168172.
  • Robinson, M.: Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment. Pharmacol. Ther. 1999, 13, 510.
  • Roy, P., D. J. Venzon, K. M. Feigenbaum, P. D. Koviack, S. Bashir, J. V. Ojeaburu, F. Gibril & R. T. Jensen: Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis – A prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine(Baltimore) 2001, 80, 189222.
  • Roy, P., D. J. Venzon, H. Shojamanesh, A. Abou-Saif, P. Peghini, J. L. Doppman, F. Gibril & R. T. Jensen: Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 2000, 79, 379411.
  • Rucker, R. B., B. Lonnerdal & C. L. Keen: Intestinal absorption of nutritionally important trace elements. In: Physiology of the gastrointestinal tract, 3rd edn. Ed.L. R.Johnson. Raven Press, New York, 1994, pp. 21832202.
  • Ruscin, J. M., R. L. 2. Page & R. J. Valuck: Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann. Pharmacother. 2002, 36, 812816.
  • Saeed, Z. A., D. J. Evans, Jr., D. G. Evans, M. J. Cornelius, P. N. Maton, R. T. Jensen & D. Y. Graham: Helicobacter pylori and the Zollinger-Ellison syndrome. Dig. Dis. Sci. 1991, 36, 1518.
  • Sagar, M., I. Janczewska, A. Ljungdahl, L. Bertilsson & R. Seensalu: Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment. Pharmacol. Ther. 1999, 13, 453458.
  • Saltzman, J. R., J. A. Kemp, B. B. Golner, M. C. Pedrosa, G. E. Dallal & R. M. Russell: Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J. Amer. Coll. Nutr. 1994, 13, 584591.
  • Sanduleanu, S., M. Stridsberg, D. Jonkers, W. Hameeteman, I. Biemond, G. Lundqvist, C. Lamers & R. W. Stockbrügger: Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment. Pharmacol. Ther. 1999, 13, 145153.
  • Sandvik, A. K., E. Brenna & H. L. Waldum: Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound. Aliment. Pharmacol. Ther. 1997, 11, 10131018.
  • Schafer, L. W., D. E. Larson, L. J. 3. Melton, J. A. Higgins & A. R. Zinsmeister: Risk of development of gastric carcinoma in patients with pernicious anemia: a population-based study in Rochester, Minnesota. Mayo Clin. Proc. 1985, 60, 444448.
  • Schenk, B. E., H. P. M. Festen, E. J. Kuipers, E. C. Klinkenberg-Knol & G. M. Meuwissen: Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment. Pharmacol. Ther. 1996, 10, 541545.
  • Schenk, B.E., E. J. Kuipers, E. C. Klinkenberg-Knol, E. Bloemena, G. F. Nelis, H. P. M. Festen, E. H. Jansen, I. Biemond, C. B. Lamers & S. G. Meuwissen: Hypergastrinemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment. Pharmacol. Ther. 1998, 12, 605612.
  • Schenk, B. E., E. J. Kuipers, E. C. Klinkenberg-Knol, E. C. Bloemena, M. Sandell, G. F. Nelis, P. Snel, H. P. Festen & S. G. Meuwissen: Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment. Pharmacol. Ther. 1999, 13, 13431346.
  • Schwizer, W., M. Thumshirn, J. Dent, I. Guldenschuh, D. Menne, G. Cathomas & M. Fried: Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001, 357, 17381742.
  • Seetharam, B.: Gastrointestinal absorption and transport of cobalamin (vitamin B12). In: Physiology of the gastrointestinal tract. Third edn. Eds.L. R.Johnson, D. H.Alpers, J.Christensen, E. D.Jacobson & J. H.Walsh. Raven Press, New York, 1994, pp. 19972026.
  • Sharma, V. R., M. A. Brannon & E. A. Carloss: Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med. J. 2004, 97, 887889.
  • Shulkes, A. & G. S. Baldwin: Biology of gut cholecystokinin and gastrin receptors. Clin. Exp. Pharmacol. Physiol. 1997, 24, 209216.
  • Singh, P., A. Indaram, R. Greenberg, V. Visvalingam & S. Bank: Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J. Gastroenterol. 2000, 789792.
  • Sjöblom, S. M., P. Sipponen, S. L. Karonen & H. J. Jarvinen: Mucosal argyrophil endocrine cells in pernicious anaemia and upper gastrointestinal carcinoid tumours J. Clin. Pathol. 1989, 42, 371377.
  • Skikne, B. S., S. R. Lynch & J. D. Cook: Role of gastric acid in food iron absorption. Gastroenterology 1981, 81, 10681071.
  • Smith, A. D., D. Gillen, K. M. Cochran, E. El-Omar & K. E. McColl: Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers. Amer. J. Gastroenterol. 1999, 94, 12091213.
  • Smith, A. M. & S. A. Watson: Review article: gastrin and colorectal cancer. Aliment. Pharmacol. Ther. 2000, 14, 12311247.
  • Smith, J. P., W. B. Stanley, M. F. Verderame & I. S. Zagon: The functional significance of the cholecystokinin-C (CCK-C) receptor in human pancreatic cancer. Pancreas 2004, 29, 271277.
  • Smith, J. T., C. Gavey, C. U. Nwokolo & R. E. Pounder: Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment. Pharmacol. Ther. 1990, 4 (Suppl. 1), 4763.
  • Sobhani, I., T. Lehy, P. Laurent-Puig, G. Cadiot, P. Ruszniewski & M. Mignon: Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology 1993, 105, 2230.
  • Solcia, E., C. Bordi, W. Creutzfeldt, Y. Dayal, A. D. Dayan, S. Falkmer, L. Grimelius & N. Havu: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988, 41, 185200.
  • Solcia, E., C. Capella, R. Fiocca, G. Rindi & J. Rosai: Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Amer. J. Surg. Pathol. 1990, 14, 503513.
  • Solcia, E., R. Fiocca, N. Havu, A. Dalvag & R. Carlsson: Gastric endocrine cells and gastritis in patients receiving long- term omeprazole treatment. Digestion 1992, 51 (Suppl. 1), 8292.
  • Solcia, E., R. Fiocca, L. Villani, O. Luinetti & C. Capella: Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Amer. J. Surg. Pathol. 1995, 19, S1S7.
  • Solcia, E., G. Rindi, N. Havu & G. Elm: Qualitative studies of gastric endocrine cells in patients treated longterm with omeprazole. Scand. J. Gastroenterol. 1989, 24, 129137.
  • Solcia, E., G. Rindi, S. LaRosa & C. Capella: Morphological, molecular, and prognostic aspects of gastric endocrine tumors. Microsc. Res. Tech. 2000, 48, 339348.
  • Sonnenberg, A. & H. B. El-Serag: Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J. Biol. Med. 1999, 72, 8192.
  • Spencer, A. J., T. A. Barbolt, D. C. Henry, C. T. Eason, R. J. Sauerschell & F. W. Bonner: Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate. Toxicol. Pathol. 1989, 17, 715.
  • Stewart, C. A., B. Termanini, V. E. Sutliff, J. Serrano, F. Yu, F. Gibril & R. T. Jensen: Assessment of the risk of iron malabsorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment. Pharmacol. Ther. 1998, 12, 8398.
  • Stolte, M., A. Meining, J. M. Schmitz, T. Alexandridis & E. Seifert: Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 1998, 12, 247253.
  • Strader, D. B., S. Benjamin, M. Orbuch, I. A. Lubensky, C. Weber, F. Gibril, R. T. Jensen & D. M. Metz: Esophageal function and occurrence of Barrett's esophagus in Zollinger-Ellison syndrome. Digestion 1995, 56, 347356.
  • Sundler, F., R. Hakanson, E. Carlsson, H. Larsson & H. Mattsson: Hypergastrinemia after blockade of acid secretion in the rat: trophic effects. Digestion 1986, 35, 5669.
  • Svendsen, J. H., C. Dahl, L. B. Svendsen & P. M. Christiansen: Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scand. J. Gastroenterol. 1986, 21, 1620.
  • Symonds, D. A. & H. E. Ramsey: Adenocarcinoma arising in Barrett's esophagus with Zollinger-Ellison syndrome. Amer. J. Clin. Pathol. 1980, 73, 823826.
  • Takaishi, S., G. Cui, D. M. Frederick, J. E. Carlson, J. Houghton, A. Varro, G. J. Dockray, Z. Ge, M. T. Whary, A. B. Rogers, J. G. Fox & T. C. Wang: Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 2005, 128, 19651983.
  • Takhar, A. S., O. Eremin & S. A. Watson: The role of gastrin in colorectal carcinogenesis. Surgeon 2004, 2, 251257.
  • Termanini, B., F. Gibril, V. E. Sutliff, III, F. Yu, D. J. Venzon & R. T. Jensen: Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Amer. J. Med. 1998, 104, 422430.
  • Thomas, R. P., M. R. Hellmich, C. M. Townsend, Jr. & B. M. Evers: Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues Endocr. Rev. 2003, 24, 571599.
  • Uemura, N., S. Okamoto, S. Yamamoto, N. Matsumura, S. Yamaguchi, M. Yamakido, K. Taniyama & N. S. R. J. Sasaki: Helicobacter pylori infection and the development of gastric cancer. New Engl. J. Med. 2001, 345, 784789.
  • Valuck, R. J. & J. M. Ruscin: A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J. Clin. Epidemiol. 2004, 57, 422428.
  • Van Nieuwenhove, Y., T. De Backer, D. Chen, R. Hakanson & G. Willems: Gastrin stimulates epithelial cell proliferation in the oesophagus of rats. Virchows Arch. 1998, 432, 371375.
  • Verdu, E. F., D. Armstrong, R. Fraser, F. Viani, J. P. Idstrom, C. Cederberg & A. L. Blum: Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995a, 36, 539543.
  • Verdu, E. F., D. Armstrong, J. P. Idstrom, J. Labenz, M. Stolte, G. Dorta, G. Borsch & A. L. Blum: Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole Gut 1995b, 37, 743748.
  • Waldum, H. L., S. Aase, I. Kvetnoi, E. Brenna, A. K. Sandvik, U. Syversen, G. Johnsen, L. Vatten & J. M., Polak: Neuroendocrine differentiation in human gastric carcinoma Cancer 1998a, 83, 435444.
  • Waldum, H. L., J. S. Arnestad, E. Brenna, I. Eide, U. Syversen & A. K. Sandvik: Marked increase in gastric acid secretory capacity after omeprazole treatment Gut 1996, 39, 649653.
  • Waldum, H. L. & E. Brenna: Personal review: is profound acid inhibition safe? Aliment- Pharmacol. Ther. 2000, 14, 1522.
  • Waldum, H. L., E. Brenna & A. K. Sandvik: Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections Expert Opin. Drug Saf 2002, 1, 2938.
  • Waldum, H. L., I. M. Kvetnoi, R. Sylte, B. Schulze, T. C. Martinsen & A. K. Sandvik: The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell. J Mol. Endocrinol. 1998b, 20, 111117.
  • Wang, T. C., C. A. Dangler, D. Chen, J. R. Goldenring, T. Koh, R. Raychowdhury, R. J. Coffey, S. Ito, A. Varro, G. J. Dockray & J. G. Fox: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer Gastroenterology 2000, 118, 3647.
  • Wangberg, B., O. Nilsson, E. Theodorsson, I. M. Modlin, A. Dahlström & H. Ahlman: Are enterochromaffinlike cell tumours reversible? An experimental study on gastric carcinoids induced in Mastomys by histamine2-receptor blockade. Regul. Pept. 1995, 56, 1933.
  • Weber, H. C., D. J. Venzon, R. T. Jensen & D. C. Metz: Studies on the interrelation between ZollingerEllison syndrome, Helicobacter pylori and proton pump inhibitor therapy. Gastroenterology 1997, 112, 8491.
  • Wilder-Smith, C. H. & H. S. Merki: Tolerance during dosing with H2-receptor antagonists. An overview. Scand. J. Gastroenterol. Suppl. 1992, 193, 1419.
  • Wolters, M., A. Strohle & A. Hahn: Cobalamin: a critical vitamin in the elderly. Prev. Med. 2004, 39, 12561266.
  • Wu, J. C., F. K. Chan, J. Y. Ching, W. K. Leung, Y. Hui, R. Leong, S. C. Chung & J. J. Sung: Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004, 53, 174179.
  • Ye, W. & O. Nyren: Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. Gut 2003, 52, 938941.
  • Yeomans, N. D. & J. Dent: Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment. Pharmacol. Ther. 2000, 14, 267271.
  • Younes, M.: Can proton pump inhibitors be blamed for the rising incidence of esophageal cancer? [Letter to Ed.]. Gastroenterology 2003, 125, 1912.
  • Yu, F., D. J. Venzon, J. Serrano, S. U. Goebel, J. L. Doppman, F. Gibril & R. T. Jensen: Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J. Clin. Oncol. 1999, 17, 615630.